Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings

Document Type

Article

Publication Date

6-1-2018

Publication Title

Infectious disease clinics of North America

Abstract

Chronic Hepatitis Cohort Study (CHeCS) publications using data from "real-world" patients with hepatitis C virus (HCV) have described demographic disparities in access to care; rates of advanced liver disease, morbidity, and mortality (2.5%-3.5% per year during 2006-10, although only 19% of all CHeCS decedents, and just 30% of those with deaths attributed to liver disease, had HCV listed on death certificate); substantial comorbidities, such as diabetes, advanced liver fibrosis (29% prevalence), renal disease, and depression, and partial reversal of all these with successful antiviral therapy; patient risk behaviors; and use of noninvasive markers to assess liver disease.

Medical Subject Headings

Adult; Aged; Antiviral Agents/therapeutic use; Cohort Studies; Female; Hepacivirus/drug effects; Hepatitis C; Chronic/complications/diagnosis/drug therapy/mortality; Humans; Liver Cirrhosis/drug therapy/mortality/pathology; Male; Middle Aged; Observational Studies as Topic; Patient Reported Outcome Measures; Ribavirin/therapeutic use; Time Factors; Young Adult; Cirrhosis; Comorbidities; Direct-acting antiviral; Hepatitis C; Mortality; Real-world cohort; Sustained viral response

PubMed ID

29778254

Volume

32

Issue

2

First Page

253

Last Page

268

Find It @ Sladen

Share

COinS